TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1483820

Group type: EXPERIMENTAL
Intervention: Questionnaires with portion sizes included
Number of subjects: 6783

Group type: COMPARATOR
Intervention: Questionnaires without portion sizes
Number of subjects: 6783

Group type: EXPERIMENTAL
Intervention: Questionnaires with decreasing order of frequency categories
Number of subjects: 6783

Group type: COMPARATOR
Intervention: Shorter basic form questionnaires
Number of subjects: 6783
Study: 3993604

Group type: EXPERIMENTAL
Intervention: Milk with thiocyanate concentration of 19 mg/l
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Milk with thiocyanate concentration of 3.6 mg/l
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Milk with iodine concentration of 0.1 mg/l and thiocyanate concentration of 19 mg/l
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Milk with iodine concentration of 0.1 mg/l and thiocyanate concentration of 3.6 mg/l
Number of subjects: 55
Study: 30969874

Group type: EXPERIMENTAL
Intervention: Health literacy questionnaires (3 different tools)
Number of subjects: 108
Study: 30017351

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Open radical retropubic prostatectomy
Number of subjects: 326
Study: 26949830

Group type: EXPERIMENTAL
Intervention: Stroop task (mental fatigue)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reading from magazines (control)
Number of subjects: 12
Study: 24877590

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 22348423

Group type: EXPERIMENTAL
Intervention: ACT plus care as usual
Number of subjects: 90

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 90
Study: 20059794

Group type: EXPERIMENTAL
Intervention: Tailored intervention leaflet
Number of subjects: 823

Group type: COMPARATOR
Intervention: Generic leaflet (Control)
Number of subjects: 823
Study: 16918613

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 4

Group type: COMPARATOR
Intervention: (-)-alpha-bisabolol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Canola oil
Number of subjects: 4
Study: 15329377

Group type: EXPERIMENTAL
Intervention: Magnet attachment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ball attachment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bar-clip attachment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Implant treatment (all attachments)
Number of subjects: 18
Study: 11780380

Group type: EXPERIMENTAL
Intervention: PEEPe at 90% of PEEPi, stz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEPe at 100% of PEEPi, stz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PEEPe at 80% of PEEPi, stz
Number of subjects: 10
Study: 9531224

Group type: EXPERIMENTAL
Intervention: Initial intravenous heparin dose of 30,000 U/24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic activated partial thromboplastin time (APTT) achieved by 24 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subtherapeutic heparin for 24 hours
Number of subjects: 0
Study: 8438978

Group type: EXPERIMENTAL
Intervention: Treatwell intervention
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (8 companies)
Number of subjects: 13
Study: 3641900

Group type: EXPERIMENTAL
Intervention: Cold sitz baths
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warm sitz baths
Number of subjects: 40
Study: 27401241

Group type: EXPERIMENTAL
Intervention: Positivity & Rules Program (PR program)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 28185668

Group type: EXPERIMENTAL
Intervention: Budesonide transnasal nebulization (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical nasal steroids (group B)
Number of subjects: 30
Study: 26386293

Group type: EXPERIMENTAL
Intervention: Physician referral
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Radio ads
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Internet
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Ancillary Clinical Research Scientist Training (CREST) sites
Number of subjects: 1650
Study: 24456363

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (5 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22340317

Group type: EXPERIMENTAL
Intervention: Cannulated interlocking anatomical femoral intramedullary nails (Group I)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cannulated interlocking anatomical femoral intramedullary nails with tail wires (Group II)
Number of subjects: 152
Study: 19637777

Group type: EXPERIMENTAL
Intervention: Triple regimen with vitamin C (20 mg Omeprazol, 1 g amoxicillin, 250 mg clarithromycin plus 250 mg vitamin C twice daily for 2 weeks)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Triple regimen without vitamin C (20 mg Omeprazol, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 2 weeks)
Number of subjects: 214
Study: 17605895

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily) and vitamin B complex for 3 months
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study: 16355501

Group type: EXPERIMENTAL
Intervention: 5 mg alendronate daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 12010109

Group type: EXPERIMENTAL
Intervention: Brachytherapy (18 Gy of gamma radiation delivered to the target site 2 mm from an iridium‐192 source axis)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 9
Study: 10468231

Group type: EXPERIMENTAL
Intervention: Spiral computed tomography imaging
Number of subjects: 6
Study: 7541210

Group type: EXPERIMENTAL
Intervention: Phosphoramidon (NEP inhibitor)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Captopril (ACE inhibitor)
Number of subjects: 12
Study: 2090157

Group type: EXPERIMENTAL
Intervention: C31G 0.5%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C31G 0.2%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C31G 0.1%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: C31G 0.05%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 386192

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study: 30192390

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 541
Study: 28256912

Group type: EXPERIMENTAL
Intervention: Educational video about reproductive health and infertility (intervention group)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No exposure to educational video (control group)
Number of subjects: 173
Study: 26122088

Group type: EXPERIMENTAL
Intervention: Passive movement and active exercise from experienced physiotherapists, 3 times a week for 12 weeks
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Passive movement and active exercise from parents or caregivers at home, 3 times a week for 12 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Follow up only (control group)
Number of subjects: 147
Study: 24246378

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 20490798

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg/m²/day administered 30 min prior to etoposide infusion
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Etoposide and carboplatin infusions
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CYP3A and MDR1 SNPs
Number of subjects: 67
Study: 19238360

Group type: EXPERIMENTAL
Intervention: Surgical treatment (49 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-surgical treatment (46 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall incidence of DVT
Number of subjects: 100
Study: 16635659

Group type: EXPERIMENTAL
Intervention: Active photopheresis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham photopheresis
Number of subjects: 64
Study: 14646349

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (STI571)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-CD20 (rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide and all‐TRANS‐retinoic acid (ATRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-etodolac
Number of subjects: 0
Study: 11436877

Group type: EXPERIMENTAL
Intervention: Endocervical application of 0.5 mg dinoprostone gel (2 times during an interval of 4 hours) and intramuscular Prostin 15 M (Carboprost Tromethamine) (1 ml/h) administered 6 hours after the second application until abortion
Number of subjects: 97

Group type: COMPARATOR
Intervention: Singleton endocervical application of 0.5 mg dinoprostone gel and intramuscular Prostin 15 M (Carboprost Tromethamine) (1 ml/2 h) administered 10 hours later until abortion
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Singleton double-dose endocervical application of 0.5 mg dinoprostone gel and intramuscular Prostin 15 M (Carboprost Tromethamine) (1 ml/2 h) administered 10 hours later until abortion
Number of subjects: 97
Study: 9924227

Group type: EXPERIMENTAL
Intervention: On-site prothrombin time using CoaguChek-Plus monitor in group A
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: On-site prothrombin time using CoaguChek-Plus monitor in group B
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: On-site prothrombin time using CoaguChek-Plus monitor in group C
Number of subjects: 62
Study: 7801066

Group type: EXPERIMENTAL
Intervention: Hemiparetic patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Left hemiparetic patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Right hemiparetic patients
Number of subjects: 35
Study: 2809562

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Combined use of terbutaline and ipratropium
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 972328

Group type: EXPERIMENTAL
Intervention: Cerebral electric therapy (electrosleep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30217471

Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened beverage (SSB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water
Number of subjects: 28
Study: 28582355

Group type: EXPERIMENTAL
Intervention: Positive group psychotherapy and motivational interviewing
Number of subjects: 36
Study: 25277789

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol sublingually after delivery of the newborn
Number of subjects: 396

Group type: COMPARATOR
Intervention: Matched placebo sublingually after delivery of the newborn
Number of subjects: 396
Study: 22385133

Group type: EXPERIMENTAL
Intervention: DAG meal (10 g of DAG oil)
Number of subjects: 41

Group type: COMPARATOR
Intervention: TAG meal (TAG oil)
Number of subjects: 41
Study: 20664016

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no diabetes development)
Number of subjects: 110
Study: 18550968

Group type: EXPERIMENTAL
Intervention: Skill-based conditioning games
Number of subjects: 25

Group type: COMPARATOR
Intervention: Instructional training
Number of subjects: 25
Study: 15719076

Group type: EXPERIMENTAL
Intervention: Complete dentures with clinical remount procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Complete dentures without clinical remount procedure
Number of subjects: 100
Study: 12439805

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) plus Lamivudine (150 mg) twice daily from week 34 of gestation until labor; during labor, zidovudine and lamivudine were given every 3 hours.
Number of subjects: 106
Study: 10353554

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 40
Study: 7556988

Group type: EXPERIMENTAL
Intervention: Nicotinamide (25 mg/kg body weight for 12 months)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 2025309

Group type: EXPERIMENTAL
Intervention: Ibuprofen and Alprazolam
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 7100263

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 23
Study: 31512457

Group type: EXPERIMENTAL
Intervention: Ethibond sutures (USP 5) with 4 threads (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethibond sutures (USP 5) with 8 threads (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrabraid sutures (USP 2) with 4 threads (Group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrabraid sutures (USP 2) with 8 threads (Group D)
Number of subjects: 40
Study: 28738376

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation plus cognitive training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation alone
Number of subjects: 34
Study: 25483291

Group type: EXPERIMENTAL
Intervention: Metformin 1000mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23852610

Group type: EXPERIMENTAL
Intervention: Reduced-dose prasugrel (5 mg/d)
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 2083
Study: 21883499

Group type: EXPERIMENTAL
Intervention: 1A/1B (alternate feeding of 1-day diet A followed by 1-day diet B)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 1A/1C (alternate feeding of 1-day diet A followed by 1-day diet C)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (not explicitly defined in the abstract)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 1A/1B and 1A/1C
Number of subjects: 135
Study: 19208305

Group type: EXPERIMENTAL
Intervention: Active depressor treatment with lisinopril or labetalol
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pressor arm (not specified treatment)
Number of subjects: 180
Study: 17558683

Group type: EXPERIMENTAL
Intervention: Low-dose gonadotropin-releasing hormone agonist (buserelin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16534680

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation plus partial splenic embolization (EVL + PSE)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation alone (EVL)
Number of subjects: 84
Study: 12492458

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg day(-1) for 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg day(-1) for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 17
Study: 12462824

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Mimic therapeutic touch (placebo)
Number of subjects: 11
Study: 8856491

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 65
Study: 1303630

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg administered 6-hourly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6372930

Group type: EXPERIMENTAL
Intervention: misonidazole
Number of subjects: 153
Study: 31658994

Group type: EXPERIMENTAL
Intervention: Ipilimumab with concurrent stereotactic radiation therapy (50 Gy in 4 fractions or 60 Gy in 10 fractions)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with sequential stereotactic radiation therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with concurrent stereotactic radiation therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with stereotactic radiation therapy (sequential lung group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-dose radiation to nontargeted lesions
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ipilimumab with stereotactic radiation therapy
Number of subjects: 106
Study: 27614723

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study: 26520894

Group type: EXPERIMENTAL
Intervention: Mesoglycan (60 mg, single i.m. administration)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mesoglycan (50 mg twice a day, chronic treatment for 90 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (single i.m. administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (chronic treatment for 90 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mesoglycan (chronic treatment for 90 days)
Number of subjects: 30
Study: 23418046

Group type: EXPERIMENTAL
Intervention: s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33)
Number of subjects: 49

Group type: COMPARATOR
Intervention: i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16)
Number of subjects: 49
Study: 21335930

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment for hip OA
Number of subjects: 65
Study: 19830964

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system (Scotchbond Multi‐Purpose Plus, 3M ESPE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-etch adhesive system (AdheSE, Ivoclar‐Vivadent)
Number of subjects: 30
Study: 17090236

Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Number of subjects: 100

Group type: COMPARATOR
Intervention: No pharyngeal packing
Number of subjects: 100
Study: 14695722

Group type: EXPERIMENTAL
Intervention: Nefopam at a target plasma concentration of 70 ng/ml (high dose, approximately 20 mg total)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nefopam at a target plasma concentration of 35 ng/ml (low dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 9
Study: 11721319

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5-5.0 mg daily (n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg daily (n = 17)
Number of subjects: 34
Study: 9265098

Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 8083009

Group type: EXPERIMENTAL
Intervention: Self-regulation exercise (Group B and C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rest condition (Group A)
Number of subjects: 22
Study: 3033593

Group type: EXPERIMENTAL
Intervention: 10(4) PFU of vaccine virus
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10(3) PFU of vaccine virus
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30474893

Group type: EXPERIMENTAL
Intervention: Cistanche Yishen granules (CYG)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 28222810

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 14
Study: 26260555

Group type: EXPERIMENTAL
Intervention: Lower extremity muscles endurance exercise for 20 RM followed by cardiorespiratory endurance exercise for 24-25 minutes (type I)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Lower extremity muscles endurance exercises for 10 RM followed by cardiorespiratory endurance exercises for 26-27 minutes (type II)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Throwing a tennis ball with 10 m distance for 10 minutes (type III)
Number of subjects: 212
Study: 24511715

Group type: EXPERIMENTAL
Intervention: Sublingual 200 microg of misoprostol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 21494123

Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Classic 4-port laparoscopic cholecystectomy (CLC)
Number of subjects: 43
Study: 18647729

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (SLT) - language enrichment therapy, 45 min/day for 15 weekdays
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 16409513

Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 1 hour
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 2 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 3 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 15 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (water treatment) for 1 hour
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (water treatment) for 2 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (water treatment) for 3 hours
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (water treatment) for 15 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment overnight followed by artificial saliva for 3 minutes
Number of subjects: 17
Study: 12942586

Group type: EXPERIMENTAL
Intervention: 7 g/day of inulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12973134

Group type: EXPERIMENTAL
Intervention: Lumbar instrumented fusion with posterior transpedicular screws and postoperative physiotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cognitive intervention and exercises
Number of subjects: 64
Study: 10964175

Group type: EXPERIMENTAL
Intervention: Liaison nursing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (before liaison nursing)
Number of subjects: 0
Study: 8846275

Group type: COMPARATOR
Intervention: 1% mepivacaine 7 mg.kg‐1 and normal saline 1 ml (Group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine 7 mg.kg‐1 plus clonidine 2 micrograms.kg‐1 and normal saline up to 1 ml (Group 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (Group 1)
Number of subjects: 42
Study: 1719650

Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy (ELT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Palliative endoscopic perturbation (PEP)
Number of subjects: 40